Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Tài liệu tham khảo
Diab, 1999, Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas, J Clin Oncol, 17, 1442, 10.1200/JCO.1999.17.5.1442
Di Saverio, 2008, A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma, Breast Cancer Res Treat, 111, 541, 10.1007/s10549-007-9809-z
Lacroix-Triki, 2010, Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type, J Pathol, 222, 282, 10.1002/path.2763
Cao, 2012, Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China, Ann Surg Oncol, 19, 3019, 10.1245/s10434-012-2322-6
Harrison, 2018, An update of mucinous lesions of the breast, Surg Pathol Clin, 11, 61, 10.1016/j.path.2017.09.002
Ginter, 2020, A review of mucinous lesions of the breast, Breast J, 26, 1168, 10.1111/tbj.13878
Gao, 2020, Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: a SEER-based analysis, Breast, 54, 79, 10.1016/j.breast.2020.09.003
Joneja, 2023, The spectrum of mucinous lesions of the breast, Arch Pathol Lab Med, 147, 19, 10.5858/arpa.2022-0054-RA
Marrazzo, 2020, Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis, Breast, 49, 87, 10.1016/j.breast.2019.11.002
Semiglazov, 2007, Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer, Cancer, 110, 244, 10.1002/cncr.22789
Alba, 2012, Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study, Ann Oncol, 23, 3069, 10.1093/annonc/mds132
Torrisi, 2007, Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer, Br J Cancer, 97, 802, 10.1038/sj.bjc.6603947
von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595
Tan, 2009, Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer, Am J Surg, 198, 520, 10.1016/j.amjsurg.2009.06.004
Ellis, 2017, Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons Oncology group Z1031 trial (alliance), J Clin Oncol, 35, 1061, 10.1200/JCO.2016.69.4406
Grossman, 2018, Neoadjuvant endocrine therapy: who benefits most?, Surg Oncol Clin, 27, 121, 10.1016/j.soc.2017.07.008
Provenzano, 2015, Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group, Mod Pathol, 28, 1185, 10.1038/modpathol.2015.74
Fisher, 2001, Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer, J Natl Cancer Inst Monogr, 62, 10.1093/oxfordjournals.jncimonographs.a003463
Sataloff, 1995, Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome, J Am Coll Surg, 180, 297
Ogston, 2003, A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival, Breast, 12, 320, 10.1016/S0960-9776(03)00106-1
Symmans, 2007, Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 25, 4414, 10.1200/JCO.2007.10.6823
Chollet, 2008, A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN), Cancer J, 14, 128, 10.1097/PPO.0b013e31816bdea2
Pareja, 2019, The genomic landscape of mucinous breast cancer, J Natl Cancer Inst, 111, 737, 10.1093/jnci/djy216
Parikh, 2005, GATA-3 expression as a predictor of hormone response in breast cancer, J Am Coll Surg, 200, 705, 10.1016/j.jamcollsurg.2004.12.025
Baretta, 2013, Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma, Clin Breast Cancer, 13, 156, 10.1016/j.clbc.2012.11.007
Garcia Hernandez, 2018, Her-2 positive mucinous carcinoma breast cancer, case report, Int J Surg Case Rep, 42, 242, 10.1016/j.ijscr.2017.12.025
Didonato, 2018, Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC), Histopathology, 72, 965, 10.1111/his.13451
Chen, 2021, Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma, Oncol Lett, 22, 771, 10.3892/ol.2021.13032
Barbashina, 2013, Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors, Hum Pathol, 44, 1577, 10.1016/j.humpath.2013.01.003
Sun, 2020, Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast, Mod Pathol, 33, 1945, 10.1038/s41379-020-0554-8